278 related articles for article (PubMed ID: 12370819)
21. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.
Huff V
Nat Rev Cancer; 2011 Feb; 11(2):111-21. PubMed ID: 21248786
[TBL] [Abstract][Full Text] [Related]
22. Role of the WT1 gene in Wilms' tumour.
Haber DA; Housman DE
Cancer Surv; 1992; 12():105-17. PubMed ID: 1322241
[TBL] [Abstract][Full Text] [Related]
23. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
24. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
27. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
[TBL] [Abstract][Full Text] [Related]
28. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
[TBL] [Abstract][Full Text] [Related]
29. [Molecular genetics of Wilms' tumor].
Papezová M; Mares J; Goetz P
Cas Lek Cesk; 2001 Jun; 140(11):323-7. PubMed ID: 11431850
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
31. Methylation changes in promoter and enhancer regions of the WT1 gene in Wilms' tumours.
Mares J; Kríz V; Weinhäusel A; Vodicková S; Kodet R; Haas OA; Sedlácek Z; Goetz P
Cancer Lett; 2001 May; 166(2):165-71. PubMed ID: 11311489
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
[TBL] [Abstract][Full Text] [Related]
33. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
[TBL] [Abstract][Full Text] [Related]
35. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers.
Hesson L; Dallol A; Minna JD; Maher ER; Latif F
Oncogene; 2003 Feb; 22(6):947-54. PubMed ID: 12584574
[TBL] [Abstract][Full Text] [Related]
36. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
Horiguchi K; Tomizawa Y; Tosaka M; Ishiuchi S; Kurihara H; Mori M; Saito N
Oncogene; 2003 Oct; 22(49):7862-5. PubMed ID: 14586413
[TBL] [Abstract][Full Text] [Related]
38. Molecular and cellular biology of Wilms' tumour.
Maitland NJ; Brown KW; Poirier V; Shaw AP; Williams J
Anticancer Res; 1989; 9(5):1417-26. PubMed ID: 2556071
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
[TBL] [Abstract][Full Text] [Related]
40. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.
Rastetter M; Schagdarsurengin U; Lahtz C; Fiedler E; Marsch WCh; Dammann R; Helmbold P
Histol Histopathol; 2007 Sep; 22(9):1005-15. PubMed ID: 17523078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
